Rabbit anti-Human SUMO1 Polyclonal Antibody | anti-SUMO1 antibody

SUMO1 (SUMO1, SMT3C, SMT3H3, UBL1, Small ubiquitin-related modifier 1, GAP-modifying protein 1, SMT3 homolog 3, Sentrin, Ubiquitin-homology domain protein PIC1, Ubiquitin-like protein SMT3C, Ubiquitin-like protein UBL1) (Azide free) (HRP)

Cat. Num. AAA6352559

• Gene Names: SUMO1; DAP1; GMP1; PIC1; SMT3; UBL1; OFC10; SENP2; SMT3C; SMT3H3
• Reactivity: Human
• Applications: Immunohistochemistry, ELISA, Western Blot
• Purity: Purified by Protein A Affinity Chromatography.
• Synonyms: SUMO1; Polyclonal Antibody; SUMO1 (SUMO1; SMT3C; SMT3H3; UBL1; Small ubiquitin-related modifier 1; GAP-modifying protein 1; SMT3 homolog 3; Sentrin; Ubiquitin-homology domain protein PIC1; Ubiquitin-like protein SMT3C; Ubiquitin-like protein UBL1) (Azide free) (HRP); Ubiquitin-like protein UBL1; anti-SUMO1 antibody

• Host: Rabbit
• Reactivity: Human
• Clonality: Polyclonal
• Isotype: IgG
• Purity/Purification: Purified by Protein A Affinity Chromatography.
• Form/Format: Supplied as a liquid in PBS, pH 7.2. No preservative added. Labeled with Horseradish Peroxidase (HRP).

• Applicable Applications for anti-SUMO1 antibody: Immunohistochemistry (IHC), ELISA (EIA), Western Blot (WB)
• Application Notes: IHC: 1:50-100; ELISA: 1:1,000; WB: 1:100-500; Applications are based on unconjugated antibody.
• Immunogen: SUMO1 antibody is generated from rabbits immunized with human SUMO1 recombinant protein.
• Conjugate: HRP
• Note: Preservative Free
• Preparation and Storage: Store product at 4 degree C if to be used immediately within two weeks. For long-term storage, aliquot to avoid repeated freezing and thawing and store at -20 degree C. Aliquots are stable at -20 degree C for 12 months after receipt. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer. Note: Sodium azide is a potent inhibitor of peroxidase and should not be added to HRP conjugates. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Western Blot (WB)

(Western blot analysis of SUMO1 Antibody in MCF-7 cell line lysates (35ug/lane). SUMO1 (arrow) was detected using the purified Pab.)

Immunohistochemistry (IHC)

(Formalin-fixed and paraffin-embedded human brain tissue reacted with SUMO1 Antibody, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.)

Flow Cytometry (FC/FACS)

(SUMO1 Antibody flow cytometry analysis of MCF-7 cells (bottom histogram) compared to a negative control cell (top histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.)

Immunofluorescence (IF)

(Confocal immunofluorescent analysis of SUMO1 Antibody with A375 cell followed by Alexa Fluor 488-conjugated goat anti-rabbit lgG (green).Actin filaments have been labeled with Alexa Fluor 555 phalloidin (red).DAPI was used to stain the cell nuclear (blue).)

Related Product Information for anti-SUMO1 antibody

Covalent modification of target lysines by SUMO (small ubiquitin-like modifier) modulates processes such as protein localization, transcription, nuclear transport, mitosis, DNA replication and repair, signal transduction, and viral reproduction. SUMO does not seem to be involved in protein degradation and may in fact function as an antagonist of ubiquitin in the degradation process. The SUMO family consists of SUMO1 and closely related homologs SUMO2, SUMO3, and SUMO4. Sumoylation has been shown to regulate a wide range of proteins, including MDM2, PIAS, PML, RanGAP1, RanBP2, p53, p73, HIPK2, TEL, c-Jun, Fas, Daxx, TNFRI, Topo-I, Topo-II, PARK2, WRN, Sp100, IkB-alpha, Androgen receptor (AR), GLUT1/4, CaMK, DNMT3B, TDG, HIF1A, CHD3, EXOSC9, RAD51, and viral targets such as CMV-IE1/2, EBV-BZLF1, and HPV/BPV-E1.

Product Categories/Family for anti-SUMO1 antibody

Antibodies; Ubiquitin

References

Yang, S.H., et al., Mol. Cell 13(4):611-617 (2004). Bailey, D., et al., J. Biol. Chem. 279(1):692-703 (2004). Ling, Y., et al., Nucleic Acids Res. 32(2):598-610 (2004). Pountney, D.L., et al., Exp. Neurol. 184(1):436-446 (2003). Ohshima, T., et al., J. Biol. Chem. 278(51):50833-50842 (2003).

NCBI and Uniprot Product Information

• NCBI GI #: 54792065
• NCBI GeneID: 7341
• NCBI Accession #: NP_001005781.1
• NCBI GenBank Nucleotide #: NM_001005781.1
• UniProt Accession #: P63165; P55856; Q6FGG0; Q6NZ62; Q93068; B2R4I5
• Molecular Weight: 11,557 Da
• NCBI Official Full Name: small ubiquitin-related modifier 1 isoform a
• NCBI Official Synonym Full Names: small ubiquitin-like modifier 1
• NCBI Official Symbol: SUMO1
• NCBI Official Synonym Symbols: DAP1; GMP1; PIC1; SMT3; UBL1; OFC10; SENP2; SMT3C; SMT3H3
• NCBI Protein Information: small ubiquitin-related modifier 1; sentrin; SMT3 homolog 3; GAP modifying protein 1; ubiquitin-like protein UBL1; ubiquitin-like protein SMT3C; SMT3 suppressor of mif two 3 homolog 1; ubiquitin-homology domain protein PIC1
• UniProt Protein Name: Small ubiquitin-related modifier 1
• Protein Family: Small ubiquitin-related modifier
• UniProt Gene Name: SUMO1
• UniProt Synonym Gene Names: SMT3C; SMT3H3; UBL1; SUMO-1; GMP1; Smt3C
• UniProt Entry Name: SUMO1_HUMAN

NCBI Description

This gene encodes a protein that is a member of the SUMO (small ubiquitin-like modifier) protein family. It functions in a manner similar to ubiquitin in that it is bound to target proteins as part of a post-translational modification system. However, unlike ubiquitin which targets proteins for degradation, this protein is involved in a variety of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, and protein stability. It is not active until the last four amino acids of the carboxy-terminus have been cleaved off. Several pseudogenes have been reported for this gene. Alternate transcriptional splice variants encoding different isoforms have been characterized. [provided by RefSeq, Jul 2008]

Uniprot Description

SUMO1: Ubiquitin-like protein that can be covalently attached to proteins as a monomer or a lysine-linked polymer. Covalent attachment via an isopeptide bond to its substrates requires prior activation by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I, and can be promoted by E3 ligases such as PIAS1-4, RANBP2 or CBX4. This post-translational modification on lysine residues of proteins plays a crucial role in a number of cellular processes such as nuclear transport, DNA replication and repair, mitosis and signal transduction. Involved for instance in targeting RANGAP1 to the nuclear pore complex protein RANBP2. Polymeric SUMO1 chains are also susceptible to polyubiquitination which functions as a signal for proteasomal degradation of modified proteins. May also regulate a network of genes involved in palate development. Interacts with SAE2, UBE2I, RANBP2, PIAS1 and PIAS2. Interacts with PARK2. Covalently attached to a number of proteins such as IKFZ1, PML, RANGAP1, HIPK2, SP100, p53, p73-alpha, MDM2, JUN, DNMT3B and TDG. Also interacts with HIF1A, HIPK2, HIPK3, CHD3, EXOSC9, RAD51 and RAD52. Interacts with USP25 (via ts SIM domain); the interaction weakly sumoylates USP25. Belongs to the ubiquitin family. SUMO subfamily.

Protein type: Nuclear receptor co-regulator; Ubiquitin-like modifier

Chromosomal Location of Human Ortholog: 2q33

Cellular Component: nucleoplasm; PML body; nuclear membrane; cytoplasm; dendrite; fibrillar center; nucleolus; nuclear speck; synapse; nuclear pore; nucleus

Molecular Function: protein binding; ubiquitin protein ligase binding; transcription factor binding; SUMO ligase activity

Biological Process: negative regulation of transcription factor activity; cytokine and chemokine mediated signaling pathway; PML body organization and biogenesis; palate development; DNA repair; post-translational protein modification; negative regulation of DNA binding; positive regulation of protein complex assembly; protein sumoylation; regulation of protein localization; cellular protein metabolic process; positive regulation of proteasomal ubiquitin-dependent protein catabolic process; negative regulation of transcription, DNA-dependent

Disease: Orofacial Cleft 10